

Index

A

Absolute power, 188–189, 196–198
Adaptive designs, 185, 252
Adaptive enrichment strategies, 251
Adaptive randomization
 frequentist and Bayesian approaches for, 254–256
 gastric cancer umbrella design, 266–267
 importance of, 253–254
 I-SPY 2, 265–266
 overview of, 255
 response-, 256–258
 survival outcomes, 258–265
 types of
 CARA randomization, 254
 covariate-adaptive randomization, 254
 response-adaptive randomization, 254
 restricted randomization, 254
Adaptive SIDEScreen method, 305–306
Adaptive-weight burden test (ABT), 65–68
Adaptive weights, 66, 68, 79, 81, 82
ADVENT trial, 186
AF, *see* Atrial fibrillation (AF)
ALCHEMIST, 252
ANCOVA, *see* Assessed using an analysis of covariance (ANCOVA)
Animal bioassay, 3–5
A-optimality, 117, 118, 121
Assessed using an analysis of covariance (ANCOVA), 312
A-star search algorithm, 153–154
Asthma control test, 293
ATE, *see* Average treatment effect (ATE)
Atrial fibrillation (AF), 241

ATT, *see* Average treatment effect on the treated (ATT)
Average sample size, 191
Average treatment effect (ATE), 272, 281
Average treatment effect on the treated (ATT), 272, 281

B

Bagging estimator (for variable importance), 307, 308, 314, 318
Base SIDES method, 303–305
Basket trials, 251
BATTLE, 252
Bayesian approaches
 for adaptive randomization, 254–256
 of borrowing from historical data, 242–245
 simulation procedure, 245–246
 simulation results, 246–248
Bayesian dose escalation study design
 EWOC, 226–227
 EWOC-2C, 229–231
 EWOC-PH, 227–229
 simulation, 231–236
Bayesian information criterion (BIC), 99, 111
Bayesian logistic regression model (BLRM), 226
Bayesian model, 229, 230
Bayesian network (BN), 93
Benders' decomposition, 130–131
Beta prior, 244
Bias, 273–274
BIC, *see* Bayesian information criterion (BIC)
Biconvexity, 150–153

Bilateral vein graft, 103
 Binary outcome, 244
 Blinding, 289–290
 Blood oxygenation level dependent (BOLD), 117
 BLRM, *see* Bayesian logistic regression model (BLRM)
 BMI, *see* Body mass index (BMI)
 BN, *see* Bayesian network (BN)
 Body mass index (BMI), 71
 BOLD, *see* Blood oxygenation level dependent (BOLD)
 BOLD signals, 117
 Bonferroni-type methods, 209
 Bootstrap, 301, 306–310, 313, 314, 318–320
 Branch-and-bound, 131, 134, 135, 138, 142, 143
 Burden test, 62, 63

C

CABG, *see* Coronary artery bypass graft (CABG)
 Canonical correlation analysis, 40
 CARA randomization, 254, *see also* Covariate-adjusted response adaptive (CARA) randomization
 Carcinogenicity, 3, 15
 Cardiovascular disease (CVD), 289
 CDC, *see* Centers for Disease Control and Prevention (CDC)
 CDRH, *see* Center for Device Evaluation and Radiological Health (CDRH)
 Cell enumeration algorithm, 139
 Centered log-ratio transformation, 22
 Center for Device Evaluation and Radiological Health (CDRH), 271
 Centers for Disease Control and Prevention (CDC), 50
 CER, *see* Comparative effectiveness research (CER)
 Chronic Obstructive Pulmonary Disease (COPD), 293
 CIBERSORT, 157
 Coequal rule, 209
 Companion test, 246, 248
 Comparative effectiveness research (CER), 287
 Complementary pairs stability selection (CPSS), 23
 Computational complexity, 144–145
 Conditional power, 187–188, 195
 Constancy assumption, 240, 242, 246, 247
 Continual reassessment method (CRM), 225

COPD, *see* Chronic Obstructive Pulmonary Disease (COPD)
 Coronary artery bypass graft (CABG), 288
 Covariate-adaptive randomization, 254
 Covariate-adjusted response adaptive (CARA) randomization, 254
 CPSS, *see* Complementary pairs stability selection (CPSS)
 Critical boundary, 206
 CRM, *see* Continual reassessment method (CRM)
 CVD, *see* Cardiovascular disease (CVD)

D

D-efficiency (DEFF) expression, 172
 Degree of freedom (df), 63
 Design matrix, 116–119, 122, 126
 Diffusion index approach, 40
 DLT, *see* Dose limiting toxicity (DLT)
D-optimality, 117, 170, 175, 177
 Dose and sample size adaptive (DSA), 191
 Dose limiting toxicity (DLT), 225
 Dose response modelling

- assessing parallelism in, 168–169
- optimal design background, 169–173
- robust design approaches
 - geometric and uniform designs, 177–178
 - reflection designs, 175–177
 - same-concentration designs, 173–175
 - simulation results, 178–180

Dose selection, 186, 193, 198
 Dry powder inhaler (DPI), 293
 DSA, *see* Dose and Sample size Adaptive (DSA)
 Dynamic Bayesian network modeling, 93–97
 Dynamic gene expression, 93, 94, 110
 Dynamic orthogonal component analysis, 40
 Dysmenorrhea, 311–313, 320

E

Early and late onset toxicities, 226
 Electronic data capture (EDC), 252
 Electronic medical record (EMR), 294
 EMA, *see* European Medicines Agency (EMA)
 EM algorithm, 4, 99
 EMR, *see* Electronic medical record (EMR)
 EQ-5D, *see* EuroQol-5 Dimensions (EQ-5D)
 Escalation with overdose control (EWOC), 226–229

Escalation with overdose control using proportional hazards model (EWOC-PH), 227–229
 Estimand, 272–273
 European Medicines Agency (EMA), 285
 EuroQol-5 Dimensions (EQ-5D), 294
 EWOC, *see* Escalation with overdose control (EWOC)
 EWOC-2C, *see* EWOC method incorporating the two components (EWOC-2C)
 EWOC method incorporating the two components (EWOC-2C), 229–231
 EWOC-PH, *see* Escalation with overdose control using proportional hazards model (EWOC-PH)

F

Factor model, 40
 False negative (FN), 323
 False positive (FP), 323
 Family-based kernel test (famSKAT), 66
 famSKAT, *see* Family-based kernel test (famSKAT)
 Fatal tumor, 6
 FBT, *see* Fixed-weight burden test (FBT)
 FDA, *see* Food and Drug Administration (FDA)
 FF, *see* Fluticasone furoate (FF)
 FHS, *see* Framingham heart study (FHS)
 Fixed-weight burden test (FBT), 64–65
 Fluticasone furoate (FF), 293
 fMRI, *see* Functional magnetic resonance imaging (fMRI)
 FN, *see* False negative (FN)
 FNDA, *see* Functional data analysis (FNDA)
 fNIRS, *see* Functional near-infrared spectroscopy (fNIRS)
 FOCUS4, 252
 Food and Drug Administration (FDA), 252, 271, 285
 FP, *see* False positive (FP)
 Framingham heart study (FHS), 71
 Functional data analysis (FNDA), 97
 Functional magnetic resonance imaging (fMRI), 115
 Functional near-infrared spectroscopy (fNIRS), 115
 Futility, 257

G

Gastric cancer umbrella design, 266–267
 Gastroesophageal adenocarcinoma, 266

Gaussian-Laplace-Dirichlet Model (GLAD), 130
 Gaussian process, 119
 Gene clustering, 93, 98–100, 103, 104
 Gene expression, 131
 Gene expression plasticity, 103, 104
 Gene ontology (GO), 102
 Gene regulatory network (GRN), 91
 dynamic Bayesian Network modeling, 93–97
 interpolation by parametric/nonparametric function, 97–103
 real data analyses, 103–106
 results, 107–109
 simulation process, 105–107
 Genetic association, 64, 74
 Genetic burden score, 62
 Genome-wide association studies (GWASs), 61
 Genotypic correlation, 62–64, 77
 Geometric and uniform designs, 177–178
 GLAD, *see* Gaussian-Laplace-Dirichlet Model (GLAD)
 Global OPTimization (GOP), 130–131
 branch-and-bound tree, 135
 components
 preprocessing, 140
 primal problem, 140
 relaxed dual problems, 140
 unique region identification, 140
 convergence, 138
 dual problem and lower bound, 133–135
 dual subproblem at the child node, 137–138
 initialization, 133
 Lagrange function, 135–137
 lower bound, 138
 primal problem and upper bound, 133
 GO, *see* Gene ontology (GO)
 GO-ESP data, rare variant association in, 74–77
 “Grand Opportunity” Exome Sequencing Project (GO-ESP), 63
 GRN, *see* Gene regulatory network (GRN)
 Group sequential design, 206
 GUIDE platform, 300
 GWASs, *see* Genome-wide association studies (GWASs)

H

Health technology assessment (HTA), 287, 289
 Hemodynamic response function (HRF), 117
 Hierarchical model, 244–245

- Hierarchical vector autoregression (HVAR)
 method, 36–38
- High dimensional metagenomic data
 real data analysis, 29–30
 simulation studies
 for linear regression model, 25–26
 simulation results, 26–29
 statistical methods to identify OTUs
 linear log-contrast model, 21–23
 metagenomic data, 20–21
 proposed method, 23–25
- High dimensional multivariate time series
 analysis
 factor analysis, 40–41
 hierarchical vector autoregression (HVAR)
 method, 36–38
 high dimension reduction, 41–42
 lag-weighted Lasso method, 36
 Lasso method, 35–36
 macroeconomic time series, 47
 model-based clustering, 39–40
 regularization methods, 34–35
 sexually transmitted disease data, 47–55
 simulation studies, 42–45
 Space-Time AR (STAR) Model, 38–39
- HRF, *see* Hemodynamic response function (HRF)
- HTA, *see* Health technology assessment (HTA)
- HVAR method, *see* Hierarchical Vector Autoregression (HVAR) method
- Hyperplane filtering, 154
- I**
- ICM, *see* Iterative convex minorant (ICM)
- ICS, *see* Inhaled corticosteroids (ICS)
- IDE, *see* Investigational device exemption (IDE)
- Immune cell infiltration, 157
- Incidental tumor, 6
- Infinitesimal Jackknife (variance estimator), 307
- Information matrix, 117–119, 121, 122, 124, 126
- Inhaled corticosteroids (ICS), 293
- INHANCE trial, 186
- Intention-to-treat (ITT), 291
- Interim analysis, 186, 191
- Interior point method, 154
- Interval censoring, 4, 10
- Inverse probability of censoring weights (IPCW), 291
- Investigational device exemption (IDE), 271
- Investigation of serial studies to predict therapeutic response with imaging and molecular analysis 2 (I-SPY 2), 265–266
- IPCW, *see* Inverse probability of censoring weights (IPCW)
- IPE, *see* Iterative parameter estimation (IPE)
- I-SPY 2, *see* Investigation of serial studies to predict therapeutic response with imaging and molecular analysis 2 (I-SPY 2)
- Iterative convex minorant (ICM), 5
- Iterative parameter estimation (IPE), 291
- ITT, *see* Intention-to-treat (ITT)
- J**
- Jaccard coefficient, 311
- K**
- Kaplan–Meier curves, 3
- Kaplan–Meier (KM) estimation, 261
- Kernel test, 62, 66, 67, 79
- Kriging, 119, 126
- K-stage design, 207
- L**
- LABA, *see* Novel long-acting beta2-agonist (LABA)
- Lagrange function, 135–137
- Lag-weighted Lasso method, 36
- Lasso method, 35–36
- Latent Dirichlet allocation (LDA), 157
- Late onset toxicity, 225–227
- LD, *see* Linkage disequilibrium (LD)
- LDA, *see* Latent Dirichlet allocation (LDA)
- Legendre orthogonal polynomial (LOP), 93, 97, 111
- Linear deconvolution model
 NRLM, 158–159
 simulation studies
 estimating actual mixing rates, 161–163
 in-vitro cell mixtures, 160–161
 negative correlations, 159–160
 real data analysis, 163–164
 tumor contents or noises, 161
- Linear log-contrast model, 21–23
- Linear models, 245
- Linear programming (LP), 159
- Linear regression model, 25–26
- Linkage disequilibrium (LD), 62
- Locally optimal designs (LODs), 118, 120–123

Local subgroup modeling, 300
 LODs, *see* Locally optimal designs (LODs)
 Logrank tests, 3
 Logrank-type tests, 10–11
 LOP, *see* Legendre Orthogonal Polynomials (LOP)
 Lost-to-follow-up (LTF), 278
 LP, *see* Linear programming (LP)
 LTF, *see* Lost-to-follow-up (LTF)
 LUNG-MAP, 252

M

Macroeconomic time series, 47
 MAF, *see* Minor allele frequencies (MAF)
 Magnetic resonance imaging, 115
 MAR, *see* Missing at random (MAR)
 Markov Chain Monte Carlo (MCMC), 228, 245, 254
 Maximum pseudo-likelihood estimator (MPLE), 5
 Maximum tolerated dose (MTD), 225
 MCAR, *see* Missing completely at random (MCAR)
 MCMC, *see* Markov Chain Monte Carlo (MCMC)
 MCP, *see* Minimax concave penalty (MCP)
 Mean squared error (MSE), 255
 Mean squared forecast error (MSFE), 43, 44, 48, 49, 51, 52
 Metagenomic data, 20–21
 MI, *see* Multiple imputations (MI)
 microRNA (miRNA), 77, 111
 Minimax concave penalty (MCP), 22
 Minor allele frequencies (MAF), 70
 miRNA, *see* microRNA (miRNA)
 Missing at random (MAR), 6, 292
 Missing completely at random (MCAR), 292
 Missing data, 5, 6, 12, 13, 292
 Missing not at random (MNAR), 292
 Missing value interpolation, 99
 Mixed membership matrix factorization (MMMMF)
 accuracy and convergence speed, 142–144
 algorithm
 branch-and-bound tree, 135
 check convergence, 138
 dual problem and lower bound, 133–135
 dual subproblem at the child node, 137–138
 initialization, 133
 linearized Lagrange function and qualifying constraints, 135–137

 lower bound, 138
 primal problem and upper bound, 133
 A-star search algorithm, 153–155
 Benders' decomposition, 130–131
 computational complexity, 144–145
 computational improvements
 cell enumeration algorithm, 139
 theoretical time complexity, 139–140
 contributions, 131
 Global Optimization (GOP), 130–131
 illustrative example, 141–142
 mixed membership models, 130
 problem formulation, 131–132
 proof of biconvexity, 150–153
 real data analysis, 145–146
 relaxed dual problem constraints, 147–150
 Mixed membership models, 130
 Mixing rates, 161–162
 Mixture model, 99, 157
 MMWR, *see* Morbidity and Mortality Weekly Report (MMWR)
 MNAR, *see* Missing not at random (MNAR)
 Model-based clustering, 39–40
 MONSTER, 62
 Morbidity and Mortality Weekly Report (MMWR), 50
 MPLE, *see* Maximum pseudo-likelihood estimator (MPLE)
 MR-encephalography, 116
 mRNA, 111
 MSE, *see* Mean squared error (MSE)
 MSFE, *see* Mean squared forecast error (MSFE)
 MTD, *see* Maximum tolerated dose (MTD)
 Multiple imputations (MI), 292
 Multiplicity adjusted p -value, 305, 316–317
 Multivariate normal distribution, 98, 107

N

NCI MATCH, 252
 NDMA, *see* *N*-nitrosodimethylamine (NDMA)
 Negative predictive value (NPV), 325
 Network-controlling quantitative trait loci (n QTLs), 111
 Next-generation sequencing (NGS), 252
 NGS, *see* Next-generation sequencing (NGS)
 NHLBI GO-ESP data, 71–72
 NI, *see* Non-inferiority (NI)
N-nitrosodimethylamine (NDMA), 13
 Non-Gaussian nature, 157, 158
 Non-ignorable nonresponse, 292
 Non-inferiority (NI) hypotheses, 239, 241
 Non-inferiority margin, 239

- Non-negative robust linear regression (NRLM), 158
- Nonrandomized comparative studies
analysis based on the design
1:1 matching, 280
stratification, 280–282
subgroup analysis, 282
bias, 273–274
estimands, 272–273
missing data, 281–282
propensity score methodology
1:1 matching, 275
stratification, 276
two-stage design, 276–279
- Nonsteroidal anti-inflammatory drugs (NSAIDs), 312
- Novel long-acting beta2-agonist (LABA), 293
- NPV, *see* Negative predictive value (NPV)
- n QTLs, *see* Network-controlling quantitative trait loci (n QTLs)
- NRLM, *see* Non-negative robust linear regression (NRLM)
- NSAIDs, *see* Nonsteroidal anti-inflammatory drugs (NSAIDs)
- Null distribution, 305, 307, 308, 314, 318, 319
- O**
- O’Brein-Fleming (OBF) boundary, 206
- OMM, *see* Optimal medical management (OMM)
- OpenBUGS, 254
- Operational taxonomic units (OTU), 20
- Optimal adaptive phase III design
absolute power, 188–189, 196–198
average sample size, 191
conditional power, 187–188, 195
design evaluation
complex configuration of $a\Delta_1$ and Δ_2 , 192–193
simple configuration of Δ_1 and Δ_2 , 192
probability to select a treatment arm, 191
total sample size M_i , 188
two-stage design, 186–187
type I error rate, 189–190, 199–202
- Optimality criterion, 117, 118, 121
- Optimal medical management (OMM), 241
- “Optimism bias,” 301
- OS, *see* Overall survival (OS)
- OTU, *see* Operational taxonomic units (OTU)
- Overall hierarchical rule, 215–216
- Overall survival (OS), 205, 289
- P**
- Partially hierarchical rule, 216–218
- Patient-Centered Outcomes Research Institute (PCORI), 291
- Patient-reported outcomes (PROs), 289, 293
- Patient rule indication method (PRIM), 300
- PBMCs, *see* Peripheral blood mononuclear cells (PBMCs)
- PCA, *see* Principal component analysis (PCA)
- PC-ABT, *see* Principal-component-based adaptive-weight burden test (PC-ABT)
- PCORI, *see* Patient-Centered Outcomes Research Institute (PCORI)
- PCTs, *see* Pragmatic clinical trials (PCTs)
- PDUFA, *see* Prescription Drug User Fee Act (PDUFA)
- Percent of variance explained (PVE), 70
- Percutaneous transluminal coronary angioplasty (PTCA), 288
- Performance goal (PG), 241–243, 246
- Peripheral blood mononuclear cells (PBMCs), 163
- Per-Protocol (PP), 291
- PERT method, 157
- PFS, *see* Progression-free survival (PFS)
- PG, *see* Performance goal (PG)
- Pituitary tumor study, 13–15
- PMAAs, *see* Premarket approvals (PMAAs)
- Pocock (POC) boundary, 206
- Positive predictive value (PPV), 325
- Positive semidefinite (PSD), 151
- Posterior probability, 243, 245–248
- Potential outcomes, 273
- Power analysis, 218–219
- Power prior, 243
- PP, *see* Per-Protocol (PP)
- PPV, *see* Positive predictive value (PPV)
- Pragmatic clinical trials (PCT)
analysis considerations
analysis population, 291–292
economic and humanistic endpoints, 293
heterogeneity of treatment effect, 292
missing data, 292
subgroup analysis, 292
design considerations
blinding, 289–290
endpoints and outcomes, 289
issues in, 287
patient population, 288
power, sample size, and multiplicity, 290–291

randomization, 290
 recruitment and practice environment,
 288–289
 history/characteristics/definition of, 286
 RCT, 285, 286
 Salford lung study, 293–295
 Pragmatic clinical trials (PCTs), 285, 286
 Pragmatic Explanatory Continuum Indicator
 Summary (PRECIS), 286
 PRECIS, *see* Pragmatic Explanatory
 Continuum Indicator Summary
 (PRECIS)
 Premarket approvals (PMAs), 239
 Prescription Drug User Fee Act (PDUFA), 295
 PRIM, *see* Patient rule indication method
 (PRIM)
 Principal component analysis (PCA), 68
 Principal-component-based adaptive-weight
 burden test (PC-ABT), 68–70
 Progression-free survival (PFS), 205, 289
 Propensity score
 first stage, 276–277
 matching, 275
 1:1 matching, 275
 second stage, 277–279
 stratification, 276, 282
 two-stage design, 276
 PROs, *see* Patient-reported outcomes (PROs)
 PSD, *see* Positive semidefinite (PSD)
 Pseudo-likelihood, 4, 7
 PTCA, *see* Percutaneous transluminal coronary
 angioplasty (PTCA)
 PVE, *see* Percent of variance explained (PVE)

Q

QoL, *see* Quality of life (QoL)
 QP, *see* Quadratic programming (QP)
 Q-Q plot, *see* Quantile-quantile (Q-Q) plot
 Quadratic programming (QP), 157
 Qualifying constraints, 134
 Quality of life (QoL), 289
 Quantile-quantile (Q-Q) plot, 74, 78
 Quantitative trait, 61, 63, 71, 79, 80

R

Rabbit model, 103–106
 RACA, *see* Response-adaptive covariate-
 adjusted randomization (RACA)
 Radio frequency (RF), 241
 Randomization, 290
 Randomized and controlled clinical trials
 (RCT), 185, 271, 285, 286

Rank preserving structural failure time model
 (RPSFTM), 291
 RCT, *see* Randomized and controlled clinical
 trials (RCT)
 Real data analysis, 29–30, 103–106, 145–146
 Real world data (RWD), 271, 281
 Real-world evidence (RWE), 285
 Receiver operating characteristic (ROC), vii
 Reflection designs, 175–177
 Reinforced non-inferiority design, 241–242
 Relaxed dual, 133–135
 Replicability measures (for subgroup
 identification), 310–311
 Resampling, 301
 Response-adaptive covariate-adjusted
 randomization (RACA), 268
 Response-adaptive randomization, 254
 Restricted randomization, 254
 Retrospective multiple variant association test
 adaptive-weight burden test, 65–68
 assessment of type I error, 72–73
 fixed-weight burden test, 64–65
 NHLBI GO-ESP data, 71–72
 PC-ABT, 68–70
 power comparison, 73–74
 principal component analysis (PCA), 68–70
 rare variant association in GO-ESP data,
 74–77
 simulation studies, 70–71
 Retrospective score test, 63
 RF, *see* Radio frequency (RF)
 Robust linear model (RLM), 161
 ROC, *see* Receiver operating characteristic
 (ROC)
 ROC curve
 information, 325–326
 test performance and diagnostic errors,
 323–325
 RPSFTM, *see* Rank preserving structural
 failure time model (RPSFTM)
 RWD, *see* Real world data (RWD)
 RWE, *see* Real-world evidence (RWE)

S

SAEs, *see* Serious adverse events (SAEs)
 Salford lung study (SLS), 293–295
 Same-concentration designs, 173–175
 Sample size determination, 186, 188, 193, 194
 SBP, *see* Systolic blood pressure (SBP)
 Serious adverse events (SAEs), 294
 Sexually transmitted disease (STD), 47
 data, 47–55
 Šidák adjustment, 305

- SIDEScreen method, 300
 SIDES method, 300
 Signal to noise ratio (SNR), 73
 Signature matrix, 163, 164
 Single nucleotide polymorphism (SNP), 61
 SKAT-O, 62
 SLS, *see* Salford Lung Study (SLS)
 SNP, *see* Single nucleotide polymorphism (SNP)
 SNR, *see* Signal to noise ratio (SNR)
 Sobol sequence, 120
 SOC, *see* Standard of care (SOC)
 Space filling, 120
 Space-Time AR (STAR) model, 38–39
 Splitting criterion (for subgroup identification), 303, 316
 Stagewise hierarchical rule, 210–215
 Standard of care (SOC), 287
 State space model, 40
 STD, *see* Sexually transmitted disease (STD)
 Stimulus sequence, 115, 116
 Stochastic SIDEScreen method, 306–308
 Subgroup, 309–311
 analysis, 282, 292
 Subpopulation evaluation
 adaptive SIDEScreen method, 305–306
 analysis of the case study, 315–319
 applying methodology to a cross-over study, 302–303
 base SIDES method, 303–305
 bias-corrected estimates, 309–310
 case study, 311–313
 replicability measures, 310–311
 simulation study, 313–315
 stochastic SIDEScreen method, 306–308
 Superiority, 257
 Support vector regression (SVR), 157
 Survival analysis, 3
 Survival-sacrifice data, 4, 5
 Survival-sacrifice experiment, 3
 SVR, *see* Support vector regression (SVR)
 Systolic blood pressure (SBP), 71, 77
- T**
 Targeted therapy, 207
 Temporal resolution, 115, 116
 Threshold, 300, 305–308, 317–319
 Time series, 115
 Time to repetition, 116
- Time-weighted average pain intensity (TWAPI), 312
 TNR, *see* True negative rate (TNR)
 TPR, *see* True positive rate (TPR)
 Transcriptional time lag, 95, 101
 Transfer function model, 40
 Trial length, 230
 True negative rate (TNR), 27
 True positive rate (TPR), 27
 TSDD method, 301
 Tumor, nonparametric inference on
 data structure, 5–7
 log rank-type tests, 10–11
 nonparametric estimation, 7–10
 pituitary tumor study, 13–16
 simulation studies, 11–13
 TWAPI, *see* Time-weighted average pain intensity (TWAPI)
 Two-stage adaptive phase III trial design, 186, 193
 Two-stage design, 276
 Type I error rate, 189–190, 199–202
- U**
 Umbrella (or platform) trials, 251
- V**
 VAR, *see* Vector autoregressive (VAR)
 Variable importance, 301, 305, 307, 309, 314–316, 318–320
 VARMA, *see* Vector autoregressive moving average (VARMA)
 Vascular smooth muscle cells (VSMCs), 76
 Vector autoregressive (VAR), 33
 Vector autoregressive moving average (VARMA), 33
 Virtual Twins, 301
 VSMCs, *see* Vascular smooth muscle cells (VSMCs)
- W**
 Weibull distribution, 263
 WINBUGS, 254
- Z**
 Zaslavsky's theorem, 138, 139